SCHEMBL709374

SCHEMBL709374

O=C(O)c1ccc(/C=C/c2cnc3ccccc3n2)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 9/20 0.52
NPC1 O15118 8/20 0.52
MEN1 O00255 4/20 0.51
KMT2A Q03164 4/20 0.51
ATM Q13315 1/20 0.51
PAX8 Q06710 1/20 0.51
KDM4E B2RXH2 5/20 0.49
SMN1; SMN2 Q16637 5/20 0.49
POLB P06746 3/20 0.49
ALDH1A1 P00352 4/20 0.49
HPGD P15428 1/20 0.49
ALOX15 P16050 1/20 0.49
HSD17B10 Q99714 1/20 0.49
CYSLTR2 Q9NS75 1/20 0.48
CYSLTR1 Q9Y271 1/20 0.48
MGAM O43451 1/20 0.46
PKM P14618 2/20 0.46
PIM1 P11309 1/20 0.46
THRB P10828 2/20 0.45
GFER P55789 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL709375 1.00 RAB9A (0.52) RAB9ANPC1MEN1KMT2AATM
SCHEMBL12923109 0.86 PAX8 (0.63) RAB9ANPC1MEN1KMT2APAX8
SCHEMBL711460 0.84 KDM4E (0.59) RAB9ANPC1MEN1KMT2APAX8
SCHEMBL711461 0.84 KDM4E (0.59) RAB9ANPC1MEN1KMT2APAX8
SCHEMBL5095731 0.84 ALDH1A1 (0.53) RAB9ANPC1MEN1KMT2AKDM4E
SCHEMBL5095728 0.84 ALDH1A1 (0.53) RAB9ANPC1MEN1KMT2AKDM4E
SCHEMBL707639 0.83 RAB9A (0.54) RAB9ANPC1MEN1KMT2APAX8
SCHEMBL707640 0.83 RAB9A (0.54) RAB9ANPC1MEN1KMT2APAX8
SCHEMBL712709 0.81 RAB9A (0.64) RAB9ANPC1MEN1KMT2APAX8
SCHEMBL708673 0.81 PAX8 (0.56) RAB9ANPC1MEN1KMT2AATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8124625-B2 enhancing the expression of apoAI; prevention or therapy of dislipidemia SHIONOGI & CO., LTD. (JP) 2012-02-28 US disclosed
US-8124625-B2 enhancing the expression of apoAI; prevention or therapy of dislipidemia SHIONOGI & CO., LTD. (JP) 2012-02-28 US disclosed
US-8124625-B2 enhancing the expression of apoAI; prevention or therapy of dislipidemia SHIONOGI & CO., LTD. (JP) 2012-02-28 US disclosed
US-8053445-B2 Utilities of olefin derivatives SHIONOGI & CO., LTD. (JP) 2011-11-08 US disclosed
US-8053445-B2 Utilities of olefin derivatives SHIONOGI & CO., LTD. (JP) 2011-11-08 US disclosed
US-8053445-B2 Utilities of olefin derivatives SHIONOGI & CO., LTD. (JP) 2011-11-08 US disclosed
US-20090036457-A1 Utilities of olefin derivatives YAMAMORI TERUO 2009-02-05 US disclosed
US-20090036457-A1 Utilities of olefin derivatives YAMAMORI TERUO 2009-02-05 US disclosed
US-20090036457-A1 Utilities of olefin derivatives YAMAMORI TERUO 2009-02-05 US disclosed
US-20040242615-A1 Utilities of olefin derivatives SHIONOGI & CO., LTD. (JP) 2004-12-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040242615-A1 Utilities of olefin derivatives APOL1, NR1H2, APOB RAB9A 4723/4885NPC1 19/4885MEN1 3997/4885
US-20090036457-A1 Utilities of olefin derivatives APOL1, APOB, NR1H2 RAB9A 4606/4885NPC1 48/4885MEN1 3163/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.